Spontaneous portosystemic shunt diameter predicts liver function after balloon-occluded retrograde transvenous obliteration

Akihisa Tatsumi, * Shinya Maekawa, * Leona Osawa, * Ryo Katoh, * Yasuyuki Komiyama, * Natsuko Nakakuki, * Hitomi Takada, * Shuya Matsuda, * Masaru Muraoka, * Yuichiro Suzuki, * Mitsuki Sato, * Ei Takahashi, * Mika Miura, * Fumitake Amemiya, * Shinichi Takano, * Mitsuharu Fukasawa, * Tatsuya Yamaguchi, * Yasuhiro Nakayama, * Taisuke Inoue, * Hiroki Okada, † Takuji Araki, † Hiroshi Onishi † and Nobuyuki Enomoto *

*First Department of Internal Medicine, Faculty of Medicine and Department of Radiology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Key words
balloon-occluded retrograde transvenous obliteration, hepatic venous pressure gradient, liver function, spontaneous portosystemic shunt diameter.

Abstract
Background and Aim: Recently, balloon-occluded retrograde transvenous obliteration (BRTO), performed for spontaneous portosystemic shunts (SPSS), has been receiving attention as a measure to improve liver function in cirrhotic patients with portal hypertension. However, it is unclear whether SPSS diameter is associated with changes in hepatic venous pressure gradient (HVPG) and liver function after BRTO. Methods: In 34 cirrhotic patients receiving BRTO for hepatic encephalopathy/gastric varices, the association of SPSS diameter with liver function at baseline and 6 months after BRTO and the accompanying changes in HVPG were investigated. Results: Patients had Child–Pugh (CP) scores of A/B/C (7/19/8), SPSS diameters of ≤10 mm/11–20 mm/20 mm (8/21/5), and an average observation period of 3.2 (0.3–8.5) years. SPSS diameter was significantly associated with male sex, alcohol use, and values of albumin, prothrombin time (PT%), and NH₃ at baseline. Moreover, the SPSS diameter was significantly correlated with the changes in HVPG observed upon BRTO (r = 0.55, P = 0.005), and a large shunt diameter was significantly associated with a greater increase in HVPG. At 6 months, significant improvements in albumin, PT%, bilirubin, and NH₃ were observed overall, but the improvement was marked in those with larger shunt diameters if they had CP A/B. Conclusion: SPSS diameter was strongly associated with liver function at baseline and after BRTO and also with changes in HVPG, indicating that SPSS diameter is an important predictor of BRTO outcome.

Introduction
Portal hypertension is a major problem of liver cirrhosis, causing various complications, such as ascites, esophago-gastric varices, and hepatic encephalopathy.1–2 Quality of life (QOL) and overall survival (OS) are greatly affected by these complications. As a compensatory mechanism for portal hypertension, collateral circulations known as spontaneous portosystemic shunts (SPSS) often form naturally to lower portal pressure.3–8 SPSS are an incomplete and inadequate compensatory mechanism for portal hypertension and often may exacerbate liver dysfunction further by reducing hepatic portal blood flow. In addition, large-scale studies have shown that SPSS are present in 40–70% of cirrhotic patients and may reduce the QOL and survival of these patients.7,8 On the other hand, it is not clear how SPSS are associated with liver functional reserve.

Balloon-occluded retrograde transvenous obliteration (BRTO) is a procedure developed in Japan9 for the treatment of refractory hepatic encephalopathy10–12 and intractable fundic gastric varices13–19 by the obstruction of spontaneous splenorenal (SR) or gastro-renal shunts (the major types of shunt in SPSS) through an intravenous catheter. With the accumulation of clinical cases, the BRTO procedure has gained a certain position as a treatment of refractory hepatic encephalopathy and intractable fundic gastric varices, and its effectiveness is described in the evidence-based clinical practice guideline for liver cirrhosis jointly published by the Japanese Society of Gastroenterology (JSGE) and the Japanese Society of Hepatology (JSH).20,21 In 2018, the BRTO procedure was covered by insurance in Japan. Moreover, it has been suggested that BRTO might even improve liver function.22–24 On the other hand, it is not completely clear which patients will benefit from BRTO. Conventionally, it has been considered that patients with greatly decompensated cirrhosis may not obtain a favorable outcome with BRTO, although such concrete conditions of decompensation are not evident.6
It was shown that patients with a 20% or greater increase in HVPG (hepatic venous pressure gradient) during the BRTO experienced an improvement in post-BRTO liver function. However, this result has not been confirmed in other studies and, moreover, HVPG is only obtained with an invasive catheter procedure, and the prediction of baseline HVPG as well as its change following BRTO is difficult before the catheter procedure.

Apart from BRTO, some recent studies have reported the impact of the SPSS diameter on the future pathological state of the liver. Tsuji et al. reported that the existence of a large-sized SPSS in hepatitis C cirrhosis patients treated with direct-acting antivirals (DAAs) may predict hepatic complications related to portal hypertension, after successful elimination of the virus, while Allard et al. reported that the presence of a large-sized SPSS may predict post-transplant portal thrombosis in patients undergoing liver transplantation. Based on these studies, we hypothesized that the SPSS diameter might have some role in predicting the portal hypertension-related liver function at baseline and after BRTO, although such a role has not been fully clarified to date.

In this study, we investigated the impact of the SPSS diameter on liver function at baseline and 6 months after the BRTO procedure.

### Methods

**Patients.** This is a single institutional and retrospective observational study. A total of 34 consecutive patients with liver cirrhosis who had SPSS and received BRTO for gastro-fundic varices or for hepatic encephalopathy at the University of Yamanashi Hospital from 2006 to 2018, were available for follow-up for at least 6 months after BRTO, were included. The diagnosis of cirrhosis was made based on the findings of laboratory tests and abdominal ultrasonography, computer tomography (CT), or magnetic resonance imaging (MRI). In all patients, the sizes of their SPSS shunts had been evaluated within 6 months before BRTO.

BRTO was performed as described by Kanagawa et al. In order to prevent the development of adverse events related to BRTO, the procedure was not performed (i) if the hepatic vein wedge pressure exceeded 30 mmHg after the trial balloon occlusion of the SPSS shunt, or (ii) if the hepatic vein wedge pressure increased more than 1.5 times after the trial balloon occlusion of the SPSS.

The largest SPSS diameter found by imaging in each patient was used for the analysis. The reasons for BRTO were intractable gastric varices (n = 18) and refractory hepatic encephalopathy with shunt (n = 16), and the mean observation period was 1182 days (3.24 years).

The study protocol conformed to the ethical guidelines of the 2013 Declaration of Helsinki and was approved by the

---

**Table 1** Backgrounds of the patients

| Factors                          | n = 34 |
|---------------------------------|--------|
| Median age, years (range)       | 66.5 (44–85) |
| Sex (male/female)               | 18/16  |
| Etiology (HBV/HCV/alcohol plus HCV/alcohol/PBC/NASH/unknown) | 3/16/3/4/2/3/4 |
| Indication of BRTO (GV/HE)      | 19/16  |
| Child–Pugh (A/B/C)              | 7/19/8 |
| History of HCC, n (%)           | 15 (44.1%) |
| Median observation period, days (range) | 1182 (224–5141) |
| Liver-related death, n (%)      | 17 (50%) |

BRTO, balloon-occluded retrograde transvenous obliteration; GV, gastric varices; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HE, hepatic encephalopathy; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis.

**Table 2** Characteristics of the patients classified by Child–Pugh scores

| Characteristics | All (n = 34) | A (n = 7) | B (n = 19) | C (n = 8) | P-value |
|-----------------|-------------|-----------|-----------|-----------|---------|
| Median age, years (range) | 66.5 (44–85) | 69 (61–76) | 71 (47–85) | 58.5 (44–78) | 0.125 |
| Sex (male/female) | 18/16 | 1/6 | 9/8 | 7/1 | 0.018 ** |
| Indication of BRTO (GV/HE) | 18/16 | 7/0 | 10/9 | 1/7 | 0.003 ** |
| History of HCC, n (%) | 15 (44.1%) | 1 (11%) | 11 (64%) | 3 (38%) | 0.003 ** |
| Alb (g/dL), median (range) | 3.3 (1.8–4.3) | 3.7 (3.4–4.3) | 3.3 (2.5–4.2) | 2.3 (1.8–3.1) | 0.004** |
| T-Bil (mg/dL), median (range) | 1.2 (0.3–5.6) | 1.3 (0.6–2.4) | 1.0 (0.3–2.3) | 2.1 (0.5–5.6) | 0.050 |
| AST (IU/L), median (range) | 47 (14–138) | 32 (14–91) | 45 (14–138) | 58 (36–82) | 0.438 |
| ALT (IU/L), median (range) | 27 (11–106) | 26 (17–73) | 29 (11–106) | 25 (13–65) | 0.807 |
| Pt (x 10^{-3}/μL), median (range) | 8.2 (3.1–26.2) | 9.6 (4.3–14.6) | 8.3 (3.1–26.2) | 7.2 (5.4–16.9) | 0.830 |
| PT (%), median (range) | 66 (27–91) | 78 (50–91) | 66 (53–91) | 57 (27–68) | 0.033* |
| NH₃ (μL/dL), median (range) | 104 (42–249) | 66 (42–104) | 104 (42–238) | 123 (94–249) | 0.015* |
| Diameter of shunt (mm), median (range) | 15 (6–35) | 11 (6–18) | 13 (7–32) | 22 (18–35) | < 0.001** |

*P < 0.05.
**P < 0.01.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BRTO, balloon-occluded retrograde transvenous obliteration; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; GV, gastric varices; PT, prothrombin time.
Human Ethics Review Committee of the University of Yamanashi. Informed consent was obtained from each patient.

**Statistical analysis.** Continuous variables were reported as median (range), and categorical variables were reported as number (%). Continuous variables were compared using the Mann–Whitney U test or the Wilcoxon signed-rank test, and categorical data were compared using the Chi-square test or Fisher’s exact test. Trends in the analysis were analyzed using the Cochran–Armitage test. All tests were two-sided, and \( P < 0.05 \) was defined as statistically significant.

**Results**

**Backgrounds of the patients.** Table 1 shows the backgrounds of the patients. The median age of the patients was 66.5 years, 53% were male, and the etiology of liver disease was both viral and non-viral, with 76% of patients (26/34) having

---

**Figure 1** Changes in clinical parameters 6 months after balloon-occluded retrograde transvenous obliteration (BRTO) in 34 patients. (a) Changes in serum albumin (Alb), prothrombin time (PT, %), and NH₃. (b) Changes in total bilirubin, FIB-4 index, and Child–Pugh (CP) score. Significant improvements in albumin (\( P = 0.001 \)), PT (\( P = 0.001 \)), blood ammonia (\( P = 0.001 \)), and CP score (\( P < 0.001 \)) were observed 6 months after BRTO. Total bilirubin showed a tendency to decrease (\( P = 0.241 \)), while no improvement was evident in FIB-4 (\( P = 0.497 \)). \*\( P < 0.05 \), \**\( P < 0.01 \).
Table 3  Characteristics of the patients, classified by spontaneous portosystemic shunt diameter

| Characteristics | ≤10 mm | 11–20 mm | >20 mm | P-value |
|-----------------|--------|----------|--------|---------|
| Age: ≥65 years, n (%) | 4 (50%) | 13 (62%) | 1 (20%) | 0.466 |
| Sex: Male, n (%) | 3 (38%) | 10 (48%) | 5 (100%) | 0.049* |
| Alcohol: Yes, n (%) | 0 (0%) | 3 (14%) | 4 (80%) | 0.008** |
| Alb: ≥2.5 g/dL, n (%) | 8 (100%) | 17 (81%) | 2 (40%) | 0.013* |
| T.Bil: ≥2 mg/dL, n (%) | 1 (12%) | 2 (10%) | 2 (40%) | 0.279 |
| PT: ≥70%, n (%) | 4 (50%) | 5 (24%) | 0 (0%) | 0.042* |
| Encephalopathy: Yes, n (%) | 2 (25%) | 9 (43%) | 5 (100%) | 0.015* |
| NH₃: ≥110 μg/dL, n (%) | 0 (0%) | 7 (44%) | 4 (80%) | 0.007** |
| Ascites: Yes, n (%) | 3 (38%) | 9 (43%) | 3 (60%) | 0.464 |
| Indication (HE/GV) | 2/6 | 9/21 | 5/0 | 0.002** |
| Child–Pugh A, n (%) | 3 (38%) | 4 (19%) | 0 (0%) | 0.099 |
| HCC History, n (%) | 3 (38%) | 11 (52%) | 1 (20%) | 0.745 |
| FIB-4: >5, n (%) | 6 (75%) | 15 (71%) | 3 (60%) | 0.271 |

*P < 0.05, **P < 0.01.

FIB-4, fibrosis index based on four factors; GV, gastric varices; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; HVPG, hepatic venous pressure gradient.

Figure 2  Associations between spontaneous portosystemic shunt (SPSS) diameter and baseline clinical parameters of albumin (Alb), prothrombin time (PT, %), total bilirubin, and NH₃ prior to balloon-occluded retrograde transvenous obliteration. A larger shunt diameter was observed in males (P = 0.049), albumin <2.5 g/dL (P = 0.013), PT% <70% (P = 0.042), and NH₃ ≥110 μg/dL (P = 0.007). *P < 0.05, **P < 0.01.
decompensated cirrhosis (Child-Pugh [CP] B or C). The reasons for BRTO were fundic gastric varices \((n = 18)\) and refractory hepatic encephalopathy \((n = 16)\), and the median observation period was 1182 days. One-half of these patients died of liver-related problems during the observation period. Table 2 shows the values of clinical factors stratified by CP scores. As shown here, there were more males \((P = 0.018)\), lower albumin levels \((P = 0.004)\), lower prothrombin time (PT\%) \((P = 0.033)\), and higher NH\(_3\) \((P = 0.015)\) with the increase of the CP score. The maximum SPSS diameter increased with the increase in the CP score \((P < 0.001)\).

Changes in liver function after BRTO. The effect of SPSS diameter on changes in liver function 6 months after the BRTO procedure was investigated. Significant improvements in albumin \((P = 0.002)\), PT \((P = 0.001)\), ammonia \((P = 0.001)\), and CP score \((P < 0.001)\) were observed 6 months after BRTO. Total bilirubin (T.Bil) showed a tendency to decrease \((P = 0.241)\), while no improvement was evident in FIB-4 \((P = 0.497)\) (Fig. 1).

Relationship between the SPSS diameter and baseline liver function before BRTO. Next, we focused on the SPSS diameter and examined the relationship between the shunt diameter and baseline clinical factors (Table 3, Fig. 2).

A larger shunt diameter was observed in males \((P = 0.049)\), albumin <2.5 g/dL \((P = 0.013)\), PT% <70% \((P = 0.042)\), and NH\(_3\) ≥110 μg/dL \((P = 0.007)\), while such an association was not observed in FIB-4 ≥5 \((P = 0.271)\). A large shunt diameter was also associated with alcohol intake \((P = 0.008)\). The impact of alcohol on the SPSS diameter is also demonstrated in Figure S1, Supporting information, which shows the association between the liver disease etiology and the SPSS diameter.

Relationship between SPSS diameter and changes in HVPG. We then investigated the influence of SPSS diameter on baseline and the post-balloon occluded HVPG values, as well as the change in HVPG values from baseline to after balloon occlusion \((\Delta \text{HVPG})\). In Figure 3a, it is seen that HVPG had a tendency to decrease with a large SPSS shunt diameter, as reported previously.\(^{26}\) In Figure 3b, it is also seen that HVPG had a tendency to increase after balloon occlusion with a large SPSS diameter. In particular, the SPSS diameter was significantly correlated with \(\Delta \text{HVPG}\) (Pearson correlation coefficient, \(r = 0.55, P = 0.005^{**}\)).

Relationship between SPSS diameter and changes in liver function after BRTO. Successively, we examined the influence of SPSS diameter on changes in post-BRTO liver function. When we examined the relationship between the factors...
related to liver function and SPSS diameter in all CP score patients (Fig. 4a), we found that the improvement rate of albumin, PT, and NH₃ after BRTO tended to be low when the shunt diameter was 10 mm or less, and the improvement rate was most significant in those with a diameter between 10 and 20 mm, which was especially significant for NH₃. Because the CP score is a significant confounding factor of the SPSS diameter, we next evaluated the changes in liver function classified by CP scores.

Post-BRTO changes in liver function in CP A/B patients are shown in Figure 4b. Albumin, PT, NH₃, and T.Bil had a tendency to improve with a large shunt diameter, and the changes in albumin and NH₃ were significant. On the other hand, such a clear relationship was not observed in CP C patients, as shown in Figure 4c.

**Changes in esophago-gastric varices and ascites after BRTO.** Although BRTO might be a promising procedure for the improvement of hepatic functional reserve, there are still some concerns about its adverse events. To clarify the impact of BRTO on esophago-gastric varices and ascites, we investigated the changes in esophago-gastric varices and ascites 6 months after BRTO. As shown in Figure S2a,b, while gastric varices improved significantly after BRTO, esophageal varices were significantly exacerbated, although only two patients with esophageal varices reached the F3 level. In ascites, no significant change was observed after BRTO (Figure S2c). In the investigation of factors associated with post-BRTO esophageal varices, we found that post-BRTO esophageal varices showed an association with FIB-4, although such an association was not found before BRTO (Figure S3).

**Imaging examples of the SPSS.** Example CT images of two patients with SPSS of 6 and 20 mm in diameter are shown in Figure S4. We present these patients as typical cases in which
differences in the SPSS diameter are associated with the clinical course. In case A with an SPSS diameter of 6 mm, liver function was maintained as CP A (score 5) at baseline. In this patient, ΔHVPG was limited to 1 mmHg at the time of BRTO, and there was no change in the CP score 6 months after the procedure. On the other hand, in case B with an SPSS diameter of 20 mm, liver function was CP B (score 9) at baseline. In this patient, ΔHVPG was as high as 5 mmHg at the time of BRTO, and liver function improved to CP A (score 6) 6 months after the procedure.

Discussion

In this study, we found that liver function in liver cirrhosis was negatively associated with the SPSS diameter and that an increase in shunt diameter was accompanied by an exacerbation of liver dysfunction. We also found that ΔHVPG was significantly associated with the SPSS diameter. Moreover, we showed that BRTO-induced liver functional improvement was dependent on the SPSS diameter, although the ΔHVPG was limited to 1 mmHg at the time of BRTO, and liver function was maintained as CP A (score 5) at baseline. In this patient, ΔHVPG was as high as 5 mmHg at the time of BRTO, and liver function improved to CP A (score 6) 6 months after the procedure.

First, we could clearly demonstrate that the baseline liver function was associated with the diameter of the SPSS, and that albumin, T.Bil, PT%, NH₃, and hepatic encephalopathy were exacerbated with a large diameter of the SPSS. Although it has been shown earlier that a large SPSS was associated with exacerbated liver dysfunction, there have been only a few studies reporting the quantitative relationship between the SPSS diameter and liver function. From this result alone, it is not clear whether a large shunt diameter is a result or cause of exacerbated liver dysfunction; however, because SPSS are formed as a compensation for portal hypertension but may exacerbate liver function through reducing hepatic flow portal blood flow, a large diameter could be both a result and a cause of exacerbated liver function. Considering that the SPSS diameter is quantitatively associated with liver dysfunction, it could act as a simple biomarker to evaluate the status of hepatic disease and associated portal hypertension. It is also suggested that the compensatory mechanism of the SPSS for portal hypertension might be limited in patients with small SPSS diameters. In addition to the factors influencing liver function, we found that alcohol intake and male sex were also associated with a large shunt diameter, as reported in previous studies (Table 3). In our studies, middle-aged cirrhotic men with alcohol intake are the most frequent in the group of large shunts (data not shown).

Second, we showed that BRTO-induced liver functional improvement was dependent on the SPSS diameter, although the improvement was also affected by the baseline CP status. As mentioned in the Background section, SPSS occlusion by BRTO has been shown in recent years to improve liver function, and improved liver function has been reported in patients treated with BRTO for gastric varices and hepatic encephalopathy. However, no consensus has been established as an index enabling the prediction of the improvement of liver function before BRTO. Because large SPSS may be the result of a compensatory mechanism of portal hypertension, we hypothesized that the occlusion of large SPSS might improve liver function, and this study showed this to be true. Specifically, this study showed that the improvement of albumin and NH₃, as well as the improved tendency of PT% and T.Bil, might be expected more frequently after BRTO in patients with SPSS diameters of more than 10 mm when the baseline CP scores were within CP A or B (Fig. 4). However, the relationship between the shunt diameter and improvement of liver function becomes obscure in those with CP C, suggesting that the improvement of liver function may be limited in the severely decompensated liver.

Third, we also demonstrated the correlation between the shunt diameter and HVPG at baseline and post BRTO, and ΔHVPG. Although the correlation between the SPSS diameter and HVPG at baseline had been reported previously, our study is the first to report the correlation between the SPSS diameter and HVPG post BRTO and ΔHVPG. We observed that HVPG at baseline decreased as the shunt diameter increased, while HVPG increased post BRTO. Notably, ΔHVPG increased significantly in a linear fashion with the increase of the SPSS diameter, demonstrating the direct quantitative impact of the SPSS diameter on changes in HVPG after BRTO (Fig. 3). Considering that patients with large SPSS diameters might gain higher portal flow following elevation of HVPG after BRTO, it is natural that the larger the SPSS diameter, the greater the improvements in liver function. However, such a clear correlation was evident only when the baseline CP scores were within A or B, and not in C, indicating that the improvement of liver function might not parallel HVPG increase in some CP C patients, although some improvement was observed in most CP C cases. In a previous study, it was reported that an increase in HVPG of more than 20% following trial SPSS obstruction by balloon catheter at the time of BRTO could predict post-BRTO liver function improvement. In this study, we also observed that an increase of HVPG of more than 20% at the BRTO procedure was associated with an improvement of the CP score (data not shown).

It is somewhat strange that the relationship between FIB-4, an index of fibrosis, and the SPSS diameter was not clear in this study. However, all of these patients had cirrhosis and had high FIB-4 values regardless of the SPSS diameter, and therefore fibrosis is considered a necessary condition for SPSS formation. On the other hand, the present results suggest that the SPSS diameter is determined not only by liver fibrosis but also by other factors such as the sex (male) and alcohol consumption as found by their relation with the SPSS diameter.

With regard to adverse events, BRTO has been reported to cause exacerbation of esophageal varices or ascites because the portal pressure reduced by SPSS might re-increase after the shunt closure. In this study, we found exacerbation of esophageal varices as reported previously (Figure S2a,b). On the other hand, probably because severely refractory patients with ascites were excluded from the analysis, we did not see apparent refractory ascites following the BRTO procedure (Figure S2c). Interestingly, we found a significant association between esophageal varices and FIB-4 after BRTO, while such an association was vague prior to BRTO, as shown in Figure S3. We suspect that the presence of the SPSS obscured the association between the esophageal varices and liver stiffness by lowering portal pressure, but the shunt closure procedure returned the association to its original relationship. Considering the result, we may predict the post-BRTO exacerbation of esophageal varices through FIB-4 to some extent. In contrast, no evident association was found between the SPSS diameter and esophageal varices (data not shown).
This study has some limitations. It is retrospective, and the number of patients included is not large. In addition, this is a single institutional study and the patients might not represent all the characteristics of patients with SPSS shunts, because the patients included were those with intractable gastric varices and refractory hepatic encephalopathy. Since these criteria for refractoriness may vary from institution to institution, there may be a bias in the selection of patients, even when targeting those with gastric varices and refractory hepatic encephalopathy. In this study, the largest SPSS in each patient was selected for measurement, and multiple shunts or shunts other than SPSS were not considered. The impact of the SPSS diameter on overall survival was not evaluated. Moreover, we could not analyze the relationship between the SPSS diameter and discontinuation of BRTO due to pressure over-increase at the time of procedure in this study because of the lack of appropriate databases.

In conclusion, our study showed that the SPSS diameter is strongly correlated with baseline liver function in cirrhotic patients: the larger the SPSS diameter, the lower the liver function. On the other hand, the shunt diameter was also related to the effect of shunt occlusion by BRTO, and the SPSS diameter could predict the increase of HVPG after BRTO, resulting in an improvement of liver function especially in patients with compensated liver function. Taken together, this study suggests that the SPSS diameter may be a clinically simple yet important indicator to evaluate the involvement of portal hypertension in the basic liver; moreover, it may also be a clinically important surrogate to predict liver function after BRTO.

Acknowledgment

This study was partly supported by the Research Program on Hepatitis of the Japanese Agency for Medical Research and Development (AMED) Japan (Grant number: 20fk0210047h0002, 20fk0210072s0601, and 20fk0210058s0702).

References

1. de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J. Hepatol. 2015; 63: 743–52.
2. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017; 65: 310–35.
3. Allard MA, Akamatsu N, Kokudo T et al. Clinical significance of spontaneous portosystemic shunts in living donor liver transplantation. Liver Transpl. 2021; 27: 77–87.
4. Nardelli S, Riggio O, Gioia S, Puzzono M, Pelle G, Ridola L. Spontaneous porto-systemic shunts in liver cirrhosis: clinical and therapeutical aspects. World J. Gastroenterol. 2020; 26: 1726–32.
5. Rathi S, Brocco S, Formentin C et al. Spontaneous portosystemic shunts in cirrhosis: detection, implications, and clinical associations. Dig. Liver Dis. 2020; 53: 1468–75.
6. Simón-Talero M, Rocarrina D, Martinez J et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology. 2018; 154: 1694–705.e4.
7. Vidal-González I, Quiroga S, Simón-Talero M, Genescà J. Spontaneous portosystemic shunts in liver cirrhosis: new approaches to an old problem. Therap. Adv. Gastroenterol. 2020; 13: 1756284820961287.
8. Yi F, Guo X, Wang L et al. Impact of spontaneous splenorenal shunt on liver volume and long-term survival of liver cirrhosis. J. Gastroenterol. Hepatol. 2021; 36: 1694–702.
9. Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J. Gastroenterol. Hepatol. 1996; 11: 51–8.
10. Lee EW, Lee AE, Saab S, Kee ST. Retrograde transvenous obliteration (RTO): a new treatment option for hepatic encephalopathy. Dig. Dis. Sci. 2020; 65: 2483–91.
11. Lynn AM, Singh S, Congly SE et al. Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. Liver Transpl. 2016; 22: 723–31.
12. Laleman W, Simon-Talero M, Maleux G et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013; 57: 2448–57.
13. Kumanomo M, Toyonaga A, Inoue H et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: hepatic deterioration links to portosystemic shunt syndrome. J. Gastroenterol. Hepatol. 2010; 25: 1129–35.
14. Luo X, Xiang T, Wu J et al. Endoscopic cyanoacrylate injection vs BRTO for prevention of gastric variceal bleeding: a randomized controlled trial. Hepatology. 2021; 74: 2074–84.
15. Naeshiro N, Aikata H, Kakizawa H et al. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration. J. Gastroenterol. Hepatol. 2014; 29: 1035–42.
16. Ninomi T, Nishida N, Kaminou T et al. Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: long-term follow-up in 78 patients. AJR Am. J. Roentgenol. 2005; 184: 1340–6.
17. Paleti S, Nutalapati V, Fathallah J, Jeeplyam S, Rustagi T. Balloon-occluded retrograde transvenous obliteration (BRTO) versus transjugular intrahepatic portosystemic shunt (TIPS) for treatment of gastric varices because of portal hypertension: a systematic review and meta-analysis. J. Clin. Gastroenterol. 2020; 54: 655–60.
18. Park JK, Saab S, Kee ST et al. Balloon-occluded retrograde transvenous obliteration (BRTO) for treatment of gastric varices: review and meta-analysis. Dig. Dis. Sci. 2015; 60: 1543–53.
19. Yokoyama K, Yamauchi R, Shibata K et al. Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosis. Clin. Mol. Hepatol. 2019; 25: 183–9.
20. Yoshiji H, Nagoshi S, Akahane T et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol. Res. 2021; 51: 725–49.
21. Yoshiji H, Nagoshi S, Akahane T et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J. Gastroenterol. 2021; 56: 593–619.
22. Miyamoto Y, Oho K, Kumanomo M, Toyonaga A, Sata M. Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension. J. Gastroenterol. Hepatol. 2003; 18: 934–42.
23. Uehara H, Akahoshi T, Tomikawa M et al. Prediction of improved liver function after balloon-occluded retrograde transvenous obliteration: relation to hepatic vein pressure gradient. J. Gastroenterol. Hepatol. 2012; 27: 137–41.
24. Yamamoto A, Nishida N, Morikawa H et al. Prediction for improvement of liver function after balloon-occluded retrograde transvenous obliteration for gastric varices to manage portosystemic shunt syndrome. J. Vasc. Interv. Radiol. 2016; 27: 1160–7.
25. Tsujii S, Uchida Y, Uemura H et al. Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antiviral therapies in cirrhotic patients with hepatitis C virus. Hepatol. Res. 2020; 50: 512–23.
26 Nardelli S, Riggio O, Turco L et al. Relevance of spontaneous portosystemic shunts detected with CT in patients with cirrhosis. *Radiology*. 2021; 299: 133–40.
27 Dajti E, Renzulli M, Colecchia A et al. Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients. *Dig. Liver Dis.* 2021; 54: 103–10.
28 Praktiknjo M, Simón-Talero M, Römer J et al. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. *J. Hepatol.* 2020; 72: 1140–50.
29 Kobayakawa M, Ohnishi S, Suzuki H. Recent development of balloon-occluded retrograde transvenous obliteration. *J. Gastroenterol. Hepatol.* 2019; 34: 495–500.
30 Kobayakawa M, Kokubu S, Hirota S et al. Short-term safety and efficacy of balloon-occluded retrograde transvenous obliteration using ethanolamine oleate: results of a prospective, multicenter, single-arm trial. *J. Vasc. Interv. Radiol.* 2017; 28: 1108–15.e2.

**Supporting information**

Additional supporting information may be found in the online version of this article at the publisher’s website:

**Figure S1.** Relationship between the etiology of liver disease and the SPSS diameter. “Others” includes patients with primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), and unknown (n = 4). Data are expressed with box and whisker plots, where the center line represents the median, the box limits represent the interquartile range, and the whiskers represent the minimum to maximum data range. As shown here, alcohol is significantly associated with a larger SPSS diameter. *P* < 0.05, **P** < 0.01.

**Figure S2.** Impact of BRTO on esophago-gastric varices and ascites. (a) Gastric varices significantly improved at 6 months after BRTO. On the other hand, (b) esophageal varices appear significantly worsened at 6 months after BRTO. (c) No evident influence by BRTO is observed on ascites. In the evaluation of esophago-gastric varices, endoscopic information was available at both baseline and 6 months after BRTO in 29 patients. In the evaluation of ascites, the information at both baseline and 6 months after BRTO was available in 33 patients. The analysis was performed by the Wilcoxon signed-rank test. In the analysis of esophago-gastric varices, information of 29 patients available for upper endoscopic findings both at baseline and at 6 months after BRTO was used in the analysis. In the analysis of ascites, information of 33 patients available for data at baseline and at 6 months after BRTO was used in the analysis. *P* < 0.05, **P** < 0.01.

**Figure S3.** The association between FIB-4 index and esophageal varices is shown (a) at baseline and (b) at 6 months after BRTO. Those with a higher FIB-4 index had significantly worse esophageal varices at 6 months post BRTO than those with a lower FIB-4 index, but such a relationship was not evident at pre-treatment time points. Information from 29 patients available for upper endoscopic findings both at baseline and at 6 months after BRTO was used in the analysis. *P* < 0.05, **P** < 0.01.

**Figure S4.** CT images of two cases with different SPSS diameter sizes, and their clinical courses. A case with SPSS diameter of 6 mm (a) and that of 20 mm (b) are shown. (a) In this case with an SPSS diameter of 6 mm, liver function was maintained as Child–Pugh (CP) A (score 5) at baseline. ΔHVPG was limited to 1 mmHg at the time of BRTO, and there was no change in CP score 6 months after the procedure. (b) In this case with an SPSS diameter of 20 mm, liver function was CP B (score 9) at baseline. ΔHVPG was as high as 5 mmHg at the time of BRTO, and liver function improved to CP A (score 6) 6 months after the procedure.